Clinical Trials Logo

Bladder Cancer clinical trials

View clinical trials related to Bladder Cancer.

Filter by:

NCT ID: NCT00694798 Completed - Bladder Cancer Clinical Trials

Study of Mycobacterium w in BCG Refractory Superficial Transitional Cell Carcinoma of Bladder

STCC
Start date: October 2008
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to evaluate the response rate of this treatment (Mw) in patients with BCG refractory superficial transitional cell carcinoma. Other objectives include detecting the effect of Mw on Time to Tumor progression and evaluating safety.

NCT ID: NCT00666978 Completed - Lung Cancer Clinical Trials

Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking

Start date: December 2007
Phase: Phase 4
Study type: Interventional

RATIONALE: A stop-smoking plan that includes health education counseling and bupropion may help African-American smokers stop smoking. It is not yet known whether health education counseling is more effective with or without bupropion in helping African Americans stop smoking. PURPOSE: This clinical trial is studying health education counseling and bupropion to see how well they work compared with a placebo and health education counseling in helping African Americans smokers stop smoking.

NCT ID: NCT00661609 Completed - Bladder Cancer Clinical Trials

A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer

Start date: May 2008
Phase: Phase 2
Study type: Interventional

The purpose of this Phase II study is to determine if AZD4877, an experimental drug that is a novel anti-mitotic agent (Eg5 or Kinesin Spindle Protein inhibitor that interferes with tumor cell division leading to tumor growth), can reduce tumor sizes in patients with bladder cancer

NCT ID: NCT00652210 Completed - Prostate Cancer Clinical Trials

Use of Multiphoton Microscopy in the Diagnosis of Cancer

MPM
Start date: June 2005
Phase: Phase 1
Study type: Interventional

Multiphoton microscopy (MPM) has been shown to be able to image tissue at a cellular level. Our project will initially evaluated the ability of MPM imaging to distinguish normal bladder urothelium from atypical and malignant urothelium in the ex vivo setting. After development of sufficient criteria, we plan to develop an endoscopic bladder probe that will provide a non-invasive means to image the interior of the bladder at the cellular level, which would provide direct evidence of the presence of tumor without a biopsy. After exhibiting usefulness of MPM imaging for bladder cancer, we will look at other organs beginning with the colon.

NCT ID: NCT00648102 Completed - Breast Cancer Clinical Trials

Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian Cancer

CDX1307-02
Start date: January 2006
Phase: Phase 1
Study type: Interventional

This research study is for individuals who have advanced breast, colon, pancreatic, ovarian or bladder cancer. Celldex Therapeutics, Inc. is testing a form of immune therapy (vaccine) to see if it can be used to make the immune system attack the cancer. The study includes administration of additional treatments, in combination, thought to enhance the immune response effect. This study specifically administers the vaccine systemically to explore whether dendritic cell targeted vaccines can generate more robust effects via intravenous injection. (CDX 1307-02)

NCT ID: NCT00645593 Completed - Bladder Cancer Clinical Trials

Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer

Start date: March 2008
Phase: Phase 2
Study type: Interventional

This study will compare the effects, good and/or bad, of chemotherapy (Gemcitabine and Cisplatin) with or without the addition of the chemotherapy drug Cetuximab to find out which treatment is better.

NCT ID: NCT00635336 Completed - Bladder Cancer Clinical Trials

Novel Peptide Vaccination for Patients With Advanced Bladder Cancer

Start date: February 2007
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and clinical efficacy of novel vaccination for advanced bladder cancer.

NCT ID: NCT00634621 Completed - Bladder Cancer Clinical Trials

Effectiveness of Hexaminolevulinate (Hexvix) in the Diagnosis and Treatment of Patients With Non-invasive Bladder Cancer

Start date: February 2008
Phase: N/A
Study type: Observational

The purpose of this study is to determine the effectiveness of hexaminolevulinate (Hexvix) in the diagnosis and treatment of patients with non-invasive bladder cancer and if it results in a change in patient management.

NCT ID: NCT00623064 Completed - Bladder Cancer Clinical Trials

Lapatinib, Cisplatin, Gemcitabine as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urothelial Cancer

Start date: November 2007
Phase: Phase 1
Study type: Interventional

RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin, and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving lapatinib together with combination chemotherapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of lapatinib when given together with cisplatin and gemcitabine as first-line therapy in treating patients with locally advanced or metastatic urothelial cancer.

NCT ID: NCT00622973 Completed - Prostate Cancer Clinical Trials

USPIO-enhanced and Diffusion-weighted MRI for the Detection of Pelvic Lymph Node Metastases

Start date: September 2007
Phase: Phase 3
Study type: Interventional

Preoperative detection of lymph node metastases in patients with prostate or bladder cancer is crucial for selection of the appropriate treatment strategy (surgery, androgen deprivation with/or without radiation therapy or chemotherapy) and thus for patient prognosis. Until now CT or MRI have been the modalities of choice for preoperative staging procedures. However, current morphological assessment of lymph nodes based on size and shape is unable to detect smaller metastases or liable to give false positive results on lymph nodes with reactive hyperplasia. We hypothesize that USPIO-enhanced MRI combined with DW-MRI will be able to detect pelvic lymph node metastases preoperatively with high sensitivity and specificity.